The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer:opportunities for third-generation EGFR inhibitors re-challenge

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated impressive activity in EGFR T790M-positive non-small cell lung cancer (NSCLC) progressed from prior EGFR-TKIs (1,2)However, resistance inevitably occurred after approximately 10 months of treatment.

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene(EGFR)-mutations in first-line for advanced non-small cell lung cancer

The introduction of first-or second-generation epidermal growth factor receptor gene(EGFR)tyrosine kinase inhibitors(TKIs)in chemonaive patients with advanced non-small cell lung cancer(NSCLC)has radically changed the treatment in this molecular subgroup,with an improvement in progression-free survival(PFS)compared to standard chemotherapy[1].